H. Lassmann, W. Brück, and C. F. Lucchinetti, The immunopathology of multiple sclerosis: an overview, Brain Pathol, vol.17, pp.210-218, 2007.

M. Trojano, M. Tintore, X. Montalban, J. Hillert, T. Kalincik et al., Treatment decisions in multiple sclerosis-insights from real-world observational studies, Nat Rev Neurol, 2017.

M. Tintoré, . Early, and . Treatment, Int MS J, vol.14, pp.5-10, 2007.

M. Tintore, À. Rovira, J. Río, S. Otero-romero, G. Arrambide et al., Defining high, medium and low impact prognostic factors for developing multiple sclerosis, Brain, vol.138, pp.1863-74, 2015.

F. D. Lublin, S. C. Reingold, J. A. Cohen, G. R. Cutter, P. S. Sørensen et al., Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, vol.83, pp.278-86, 2014.

P. K. Stys, G. W. Zamponi, J. Van-minnen, and J. Geurts, Will the real multiple sclerosis please stand up?, Nat Rev Neurosci, vol.13, pp.507-521, 2012.

F. Cotton, H. L. Weiner, F. A. Jolesz, and C. R. Guttmann, MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals, Neurology, vol.60, pp.640-646, 2003.

R. J. Mcdonald, J. S. Mcdonald, D. F. Kallmes, M. E. Jentoft, D. L. Murray et al., Intracranial gadolinium deposition after contrast-enhanced MR imaging, Radiology, vol.275, pp.772-82, 2015.

B. Serafini, R. Magliozzi, B. Rosicarelli, R. Reynolds, T. S. Zheng et al., Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury, J Neuropathol Exp Neurol, vol.67, pp.1137-1185, 2008.

Y. Chicheportiche, P. R. Bourdon, H. Xu, Y. Hsu, H. Scott et al., TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis, J Biol Chem, vol.272, pp.32401-32411, 1997.

S. Brown, C. M. Richards, H. N. Hanscom, S. Feng, and J. A. Winkles, The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation, Biochem J, vol.371, pp.395-403, 2003.

S. Desplat-jégo, L. Feuillet, R. Creidy, I. Malikova, R. Rance et al., TWEAK is expressed at the cell surface of monocytes during multiple sclerosis, J Leukoc Biol, vol.85, pp.132-137, 2009.

S. Desplat-jégo, S. Varriale, R. Creidy, T. R. Bernard, D. Khrestchatisky et al., TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity, J Neuroimmunol, vol.133, pp.116-139, 2002.

S. Desplat-jégo, R. Creidy, S. Varriale, N. Allaire, Y. Luo et al., Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis, Clin Immunol, vol.117, pp.15-23, 2005.

D. Stephan, O. Sbai, J. Wen, P. Couraud, C. Putterman et al., TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier, J Neuroinflammation, vol.10, p.9, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00787290

A. Bitsch, J. Schuchardt, S. Bunkowski, T. Kuhlmann, and W. Brück, Acute axonal injury in multiple sclerosis correlation with demyelination and inflammation, Brain, vol.123, pp.1174-83, 2000.

B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk et al., Axonal transection in the lesions of multiple sclerosis, N Engl J Med, vol.338, pp.278-85, 1998.

A. Maarouf, J. Ferré, W. Zaaraoui, A. L. Troter, E. Bannier et al., Ultrasmall superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome, Mult Scler J, vol.22, issue.8, pp.1032-1041, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02457660

C. H. Polman, S. C. Reingold, B. Banwell, M. Clanet, J. A. Cohen et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol, vol.69, pp.292-302, 2011.

. Maarouf, 17:51 ? fast, convenient online submission ? thorough peer review by experienced researchers in your field ? rapid publication on acceptance ? support for research data, including large and complex data types ? gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over, J Transl Med, 2019.

, Ready to submit your research ? Choose BMC and benefit from

J. F. Kurtzke, Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS), Neurology, vol.33, pp.1444-52, 1983.

C. M. Poser, D. W. Paty, L. Scheinberg, W. I. Mcdonald, F. A. Davis et al., New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, vol.13, pp.227-258, 1983.

D. Bertin, D. Stephan, M. Khrestchatisky, and S. Desplat-jégo, Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases?, Front Immunol, vol.4, p.489, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01718196

C. N. Lynch, Y. C. Wang, J. K. Lund, Y. Chen, J. A. Leal et al., TWEAK induces angiogenesis and proliferation of endothelial cells, J Biol Chem, vol.274, pp.8455-8464, 1999.

A. Jakubowski, B. Browning, M. Lukashev, I. Sizing, J. S. Thompson et al., Dual role for TWEAK in angiogenic regulation, J Cell Sci, vol.115, pp.267-74, 2002.

P. Saas, J. Boucraut, P. R. Walker, A. L. Quiquerez, M. Billot et al., TWEAK stimulation of astrocytes and the proinflammatory consequences, Glia, vol.32, pp.102-109, 2000.

Y. Chicheportiche, R. Chicheportiche, I. Sizing, J. Thompson, C. B. Benjamin et al., Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies, Arthritis Res, vol.4, pp.126-159, 2002.

S. Kim, Y. Kang, W. Kim, D. Woo, Y. Lee et al., TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages, Circ J Off J Jpn Circ Soc, vol.68, pp.396-405, 2004.

S. J. Perper, B. Browning, L. C. Burkly, S. Weng, C. Gao et al., TWEAK is a novel arthritogenic mediator, J Immunol, vol.177, pp.2610-2630, 2006.

L. C. Burkly, J. S. Michaelson, K. Hahm, A. Jakubowski, and T. S. Zheng, TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease, Cytokine, vol.40, pp.1-16, 2007.

W. Brück, Y. Brück, B. Maruschak, and R. L. Friede, Mechanisms of macrophage recruitment in Wallerian degeneration, Acta Neuropathol, vol.89, pp.363-370, 1995.

W. Brück, P. Porada, S. Poser, P. Rieckmann, F. Hanefeld et al.,

, Monocyte/macrophage differentiation in early multiple sclerosis lesions, Ann Neurol, vol.38, pp.788-96, 1995.

X. Zhang, J. A. Winkles, M. C. Gongora, R. Polavarapu, J. S. Michaelson et al., TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia, J Cereb Blood Flow Metab, vol.27, pp.534-578, 2007.

A. D. Stock, J. Wen, and C. Putterman, Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway, Front Immunol, vol.4, p.484, 2013.

J. Wen, Y. Xia, A. Stock, J. S. Michaelson, L. C. Burkly et al., Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway, J Autoimmun, vol.43, pp.44-54, 2013.

H. B. Larsson and P. S. Tofts, Measurement of blood-brain barrier permeability using dynamic Gd-DTPA scanning-a comparison of methods, Magn Reson Med, vol.24, pp.174-180, 1992.

R. Liebsch, M. E. Kornhuber, D. Dietl, H. Von-gräfin-einsiedel, and B. Conrad, Blood-CSF barrier integrity in multiple sclerosis, Acta Neurol Scand, vol.94, pp.404-414, 1996.

C. L. Willis, L. Leach, G. J. Clarke, C. C. Nolan, and D. E. Ray, Reversible disruption of tight junction complexes in the rat blood-brain barrier, following transitory focal astrocyte loss, Glia, vol.48, pp.1-13, 2004.

R. Polavarapu, M. C. Gongora, J. A. Winkles, and M. Yepes, Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation, J Neurosci, vol.25, pp.10094-100, 2005.

W. Zhou, A. Liesz, H. Bauer, C. Sommer, B. Lahrmann et al., Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models, Brain Pathol, vol.23, pp.34-44, 2013.

S. J. Karlik, E. A. Grant, D. Lee, and J. H. Noseworthy, Gadolinium enhancement in acute and chronic-progressive experimental allergic encephalomyelitis in the guinea pig, Magn Reson Med, vol.30, pp.326-357, 1993.

E. E. Kwon and J. W. Prineas, Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study, J Neuropathol Exp Neurol, vol.53, pp.625-661, 1994.

M. Filippi, M. A. Rocca, F. Barkhof, W. Brück, J. T. Chen et al., Association between pathological and MRI findings in multiple sclerosis, Lancet Neurol, vol.11, pp.349-60, 2012.

D. H. Mahad, B. D. Trapp, and H. Lassmann, Pathological mechanisms in progressive multiple sclerosis, Lancet Neurol, vol.14, pp.183-93, 2015.

M. Filippi, M. A. Horsfield, H. J. Adèr, F. Barkhof, P. Bruzzi et al., Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis, Ann Neurol, vol.43, pp.499-506, 1998.

K. Schmierer, F. Scaravilli, D. R. Altmann, G. J. Barker, and D. H. Miller, Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain, Ann Neurol, vol.56, pp.407-422, 2004.